Insider plans $1.34M EXEL stock sale on NASDAQ (NASDAQ: EXEL)
Filing Impact
Filing Sentiment
Form Type
144
Rhea-AI Filing Summary
A company insider has filed a Form 144 indicating an intent to sell 30,617 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,337,035.20. The shares, classified as performance shares, were acquired from the issuer on 02/15/2026, with the same date listed for payment. The approximate sale date is 02/17/2026 on the NASDAQ market. Over the prior three months, Christopher J. Senner sold 34,278 common shares for $1,473,964.28. By signing the notice, the seller represents that they are not aware of undisclosed material adverse information about the issuer.
Positive
- None.
Negative
- None.
FAQ
What does the Form 144 filing for EXEL indicate?
The Form 144 shows an insider’s intent to sell 30,617 common shares with an aggregate market value of $1,337,035.20. It is an advance notice for a potential sale, not confirmation that the transaction has already occurred.
What type of EXEL securities are involved in this Form 144?
The securities are common stock acquired as performance shares on February 15, 2026 from the issuer. The same date is listed for payment, and the filing describes the nature of payment as not applicable, implying non-cash performance-based acquisition.
What prior EXEL stock sales are disclosed in the Form 144?
The notice reports that Christopher J. Senner sold 34,278 common shares in a prior transaction on February 13, 2026. Those shares generated gross proceeds of $1,473,964.28, covering all relevant sales in the past three months.
Which broker will handle the planned EXEL stock sale?
The planned sale is to be handled by Morgan Stanley Smith Barney LLC, Executive Financial Services, at its New York Plaza office. The shares are intended to be sold on the NASDAQ exchange, according to the details provided in the notice.
What representation does the EXEL insider make by signing Form 144?
By signing, the insider represents they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed. This representation also applies as of any Rule 10b5-1 plan adoption date.